Voyager Therapeutics Inc. (NASDAQ:VYGR) finished Wednesday with a subtraction of -$0.08 to close at $4.53, a downside of -1.74 percent. An average of 22,288,000 shares of common stock have been traded in the last five days. There was a gain of $0.66 in the past week. The last 20 days have seen an average of 15,845,181 shares traded, while the 50-day average volume stands at 6,482,192.
VYGR stock has increased by 39.38% in the last month. The company shares reached their 1-month lowest point of $2.46 on 10/05/21. With the stock rallying to its 52-week high on 01/15/21, shares of the company touched a low of $2.46 and a high of $12.65 in 52 weeks. In spite of this, the price is down -64.19% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
146 days have passed since Voyager Therapeutics Inc. (VYGR) last reported insider trading activity. Khwaja Omar, who is See remarks, most recently acquired $3,516 shares at $4.03 per share on May 21. In this transaction, the insider spent $14,169. President & CEO, Turenne Andre, disposed of 7,977 shares at a price of $7.55 on Feb 11. The insider now owns more than $60,226 worth of shares. Prior to that, Chief Financial Officer Dorval Allison went on to Sale 3,186 shares at $7.55 each on Feb 11. An amount of $24,054 was transacted.
Voyager Therapeutics Inc. (VYGR) has a trailing price-to-earnings (P/E) ratio of 9.70, which compares with the 34.65 for the broader industry and 32.30 for the sector. In the last five years, Voyager Therapeutics Inc.’s PE ratio has ranged between 12.07 and 3.825. The stock’s beta is 1.08. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.90, the price-to-book (PB) ratio at 1.54.
The quick ratio of Voyager Therapeutics Inc. for the three months ended June 29 was 6.00, and the current ratio was 6.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Voyager Therapeutics Inc.’s EBITDA margin for the year ending June 29 is 18.23%, while its operating margin for the same period stands at 5.00%. Its gross profit as reported stood at $143.74 million compared to revenue of $171.13 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Voyager Therapeutics Inc.’s return on assets was 7.30%, compared to -30.8% over the last five years. In the past year, the return on investment has been 17.70%, and the 5-year average is -56.0%. Meanwhile, the return on equity (ROE) for the past 12 months has been 12.60% and the 5-year average holds at -57.6%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Voyager Therapeutics Inc. had $25.14 million in cash. The analyst consensus anticipated Voyager Therapeutics Inc.’s latest quarter earnings to come in at -$0.71 per share, but it turned out to be -$0.8, a -12.70% surprise. For the quarter, EBITDA amounted to -$27.29 million. Shareholders own equity worth $37.94 million.
From a technical analysis perspective, let’s take a brief look at Voyager Therapeutics Inc. (VYGR) price momentum. RSI 9-day as of the close on 13 October was 64.29%, suggesting the stock is Neutral, with historical volatility in this time frame at 308.06%.
As of today, VYGR’s price is $4.67 +17.05% or $0.66 from its 5-day moving average. VYGR is currently trading +50.50% higher than its 20-day SMA and +6.34% higher than its 100-day SMA. However, the stock’s current price level is +37.69% above the SMA50 and -39.84% below the SMA200.
The stochastic %K and %D were 66.80% and 75.66%, respectively, and the average true range (ATR) was 0.58. With the 14-day stochastic at 63.23% and the average true range at 0.47, the RSI (14) stands at 63.55%. The stock has reached 0.78 on the 9-day MACD Oscillator while the 14-day reading was at 1.14.
Robert W. Baird upgraded Voyager Therapeutics Inc. (NASDAQ: VYGR) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as a a Neutral.The consensus rating for Voyager Therapeutics Inc. (VYGR) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell VYGR, while 6 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 3 others rate it as a “buy”.
What is VYGR’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $14.00, with a median target of $5.25. Taking a look at these predictions, the average price target given by analysts for Voyager Therapeutics Inc. (VYGR) stock is $6.69.